Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Analytical Performance of a Real-time PCR-based Assay for V600 Mutations in the BRAF Gene, Used as the Companion Diagnostic Test for the Novel BRAF Inhibitor Vemurafenib in Metastatic Melanoma

Analytical Performance of a Real-time PCR-based Assay for V600 Mutations in the BRAF Gene, Used... ORIGINAL ARTICLE Analytical Performance of a Real-time PCR-based Assay for V600 Mutations in the BRAF Gene, Used as the Companion Diagnostic Test for the Novel BRAF Inhibitor Vemurafenib in Metastatic Melanoma Harkanwal Halait, MS, Kelli DeMartin, MS, Sweta Shah, BS, Stephen Soviero, BS, Rachel Langland, BS, Suzanne Cheng, PhD, Grantland Hillman, MS, Lin Wu, PhD, and H. Jeffrey Lawrence, MD cancer. BRAF mutations have been identified in 40% to 1–3 Abstract: Melanomas frequently harbor BRAFV600 mutations. 60% of melanomas, where they appear to be a very Vemurafenib (RG7204/PLX4032), a small-molecule inhibitor of early event, as they are common in benign nevi. The mutant BRAF, has shown striking clinical efficacy in BRAFV600 discovery of such somatic mutations in the BRAF gene in mutant melanoma, creating the need for a well-validated com- melanoma and other human tumors has led to the clinical panion diagnostic to select patients for treatment. We describe development of specific small-molecule inhibitors of the analytic performance characteristics of the cobas 4800 BRAF mutant BRAF kinase as a targeted therapy. One such V600 Mutation Test, the test used to select patients for the pivotal molecule, vemurafenib (RG7204/PLX4032), has shown 5,6 vemurafenib trials. This real-time polymerase chain reaction assay http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Diagnostic Molecular Pathology Wolters Kluwer Health

Analytical Performance of a Real-time PCR-based Assay for V600 Mutations in the BRAF Gene, Used as the Companion Diagnostic Test for the Novel BRAF Inhibitor Vemurafenib in Metastatic Melanoma

Diagnostic Molecular Pathology , Volume 21 (1) – Mar 1, 2012

Loading next page...
 
/lp/wolters-kluwer-health/analytical-performance-of-a-real-time-pcr-based-assay-for-v600-xwGKGuKNjL

References (12)

Copyright
Copyright © 2012 by Lippincott Williams & Wilkins
ISSN
1052-9551
DOI
10.1097/PDM.0b013e31823b216f
pmid
22306669
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL ARTICLE Analytical Performance of a Real-time PCR-based Assay for V600 Mutations in the BRAF Gene, Used as the Companion Diagnostic Test for the Novel BRAF Inhibitor Vemurafenib in Metastatic Melanoma Harkanwal Halait, MS, Kelli DeMartin, MS, Sweta Shah, BS, Stephen Soviero, BS, Rachel Langland, BS, Suzanne Cheng, PhD, Grantland Hillman, MS, Lin Wu, PhD, and H. Jeffrey Lawrence, MD cancer. BRAF mutations have been identified in 40% to 1–3 Abstract: Melanomas frequently harbor BRAFV600 mutations. 60% of melanomas, where they appear to be a very Vemurafenib (RG7204/PLX4032), a small-molecule inhibitor of early event, as they are common in benign nevi. The mutant BRAF, has shown striking clinical efficacy in BRAFV600 discovery of such somatic mutations in the BRAF gene in mutant melanoma, creating the need for a well-validated com- melanoma and other human tumors has led to the clinical panion diagnostic to select patients for treatment. We describe development of specific small-molecule inhibitors of the analytic performance characteristics of the cobas 4800 BRAF mutant BRAF kinase as a targeted therapy. One such V600 Mutation Test, the test used to select patients for the pivotal molecule, vemurafenib (RG7204/PLX4032), has shown 5,6 vemurafenib trials. This real-time polymerase chain reaction assay

Journal

Diagnostic Molecular PathologyWolters Kluwer Health

Published: Mar 1, 2012

There are no references for this article.